Diabetes Care:晚期糖基化终末产物可预测早期DN

2013-07-09 完美事业 dxy

晚期糖基化终产物(AGEs)和氧化产物(OPs)增加可能会引起糖尿病肾病(DN)进展。针对这个问题,来自美国汉诺威马达特茅斯大学盖泽尔医学院医学/内分泌学系的Beisswenger博士等人进行了一项研究,他们对103名参与”糖尿病肾病自然病史研究”的1型糖尿病患者AGEs、OPs与DN进展的关系进行了研究。研究发现,三个主要的AGEs可能是重要的DN进展的早期预测指标。研究结果在线发表于2013年

晚期糖基化终产物(AGEs)和氧化产物(OPs)增加可能会引起糖尿病肾病(DN)进展。针对这个问题,来自美国汉诺威马达特茅斯大学盖泽尔医学院医学/内分泌学系的Beisswenger博士等人进行了一项研究,他们对103名参与”糖尿病肾病自然病史研究”的1型糖尿病患者AGEs、OPs与DN进展的关系进行了研究。研究发现,三个主要的AGEs可能是重要的DN进展的早期预测指标。研究结果在线发表于2013年6月18日美国的《糖尿病治疗》(Diabetes Care)杂志上。

受试者平均年龄17.6±7.4岁,平均糖尿病病程8.3 ± 4.9年。所有患者蛋白尿正常。采用电子显微镜进行肾活组织检查,测定基线至5年后的肾小球基底膜(GBM)厚度变化,作为主要研究终点,肾小球系膜体积为次要研究终点。GBM变化高四分位数患者定义为快速进展者(FPs),余下患者划分为缓慢进展者(SPs)。第5年时,采用液相-三重四极杆质谱测定10K过滤器制备的血浆滤液中AGEs(3-脱氧葡萄糖醛酮、甲基乙二醛氢化咪唑啉酮[MGHI])、羧甲基赖氨酸(CML)、羧乙基赖氨酸(CEL)和OPs(蛋氨酸亚砜和氨基己二酸)含量。

研究发现,FPs的 MGHI、CEL和CML水平较SPs显著升高。在仅含变量HbA1c的回归模型中,可预测的GBM厚度变化的比例为4.7%,当把MGHI、CEL和CML添加到回归模型中,GBM厚度变化的比例为11.6%(增加7.9%)。MGHI是一个显著的FP独立预测因子。采用logistic回归模型分析每一生物标志物与受试者属于FP的可能性间的联系,发现CML、CEL和MGHI(而不是HbA1c)与患者属于FP的可能性具有显著的相关性。

研究结果表明,这三个主要的AGEs可能是重要的DN进展的早期预测指标。


评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759321, encodeId=128a1e5932122, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 03 23:14:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901124, encodeId=3a24190112442, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Mar 14 01:14:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636713, encodeId=3def1636e13e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 24 05:14:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318278, encodeId=3dde13182e85e, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Jul 11 02:14:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759321, encodeId=128a1e5932122, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 03 23:14:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901124, encodeId=3a24190112442, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Mar 14 01:14:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636713, encodeId=3def1636e13e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 24 05:14:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318278, encodeId=3dde13182e85e, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Jul 11 02:14:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759321, encodeId=128a1e5932122, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 03 23:14:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901124, encodeId=3a24190112442, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Mar 14 01:14:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636713, encodeId=3def1636e13e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 24 05:14:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318278, encodeId=3dde13182e85e, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Jul 11 02:14:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759321, encodeId=128a1e5932122, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 03 23:14:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901124, encodeId=3a24190112442, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Mar 14 01:14:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636713, encodeId=3def1636e13e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 24 05:14:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318278, encodeId=3dde13182e85e, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Jul 11 02:14:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
    2013-07-11 lfyang

相关资讯

Diabetes:糖基化LDL致AS作用增强

  英国学者的一项研究表明,丙酮醛(MG)修饰低密度脂蛋白(LDL)可形成小而致密的LDL,其致动脉粥样硬化(AS)作用增强。这可能对糖尿病心血管风险递增和二甲双胍的心脏保护作用做出了解释。论文于2011年5月26日在线发表于《糖尿病》(Diabetes)杂志。   研究者分离出人类LDL并且在体外通过MG最低限度修饰LDL(MGmin-LDL)。研究者对MGmin-LDL的致动脉粥样硬化特征进